CN117279634A - 包含化合物smtp-7的药物组合物 - Google Patents

包含化合物smtp-7的药物组合物 Download PDF

Info

Publication number
CN117279634A
CN117279634A CN202280033984.6A CN202280033984A CN117279634A CN 117279634 A CN117279634 A CN 117279634A CN 202280033984 A CN202280033984 A CN 202280033984A CN 117279634 A CN117279634 A CN 117279634A
Authority
CN
China
Prior art keywords
pharmaceutical composition
smtp
additive
amphiphilic
castor oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033984.6A
Other languages
English (en)
Chinese (zh)
Inventor
西村直子
长谷川启子
莲见惠司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corxel Pharmaceuticals Hong Kong Ltd
Original Assignee
Bojian Massachusetts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bojian Massachusetts Co ltd filed Critical Bojian Massachusetts Co ltd
Publication of CN117279634A publication Critical patent/CN117279634A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CN202280033984.6A 2021-04-20 2022-04-20 包含化合物smtp-7的药物组合物 Pending CN117279634A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-070892 2021-04-20
JP2021070892 2021-04-20
PCT/US2022/025462 WO2022226013A1 (en) 2021-04-20 2022-04-20 Pharmaceutical composition comprising the compound smtp-7

Publications (1)

Publication Number Publication Date
CN117279634A true CN117279634A (zh) 2023-12-22

Family

ID=81648879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033984.6A Pending CN117279634A (zh) 2021-04-20 2022-04-20 包含化合物smtp-7的药物组合物

Country Status (9)

Country Link
US (1) US20240238252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525239A (cg-RX-API-DMAC7.html)
KR (1) KR20230173129A (cg-RX-API-DMAC7.html)
CN (1) CN117279634A (cg-RX-API-DMAC7.html)
AU (1) AU2022262593A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021803A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214630A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226013A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008201688A (ja) * 2007-02-16 2008-09-04 Tms Co Ltd 皮膚老化防止剤、化粧料及び皮膚外用剤
CN102470124A (zh) * 2009-07-06 2012-05-23 国立大学法人东京农工大学 细胞保护剂
US20200140450A1 (en) * 2018-11-02 2020-05-07 Showa University Chemical method of producing smtp groups or smtp-7 and intermediates used in the method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JPWO2007040082A1 (ja) 2005-10-06 2009-04-16 国立大学法人東京農工大学 腎炎治療又は予防用医薬組成物及びその製造方法
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
WO2011125930A1 (ja) 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008201688A (ja) * 2007-02-16 2008-09-04 Tms Co Ltd 皮膚老化防止剤、化粧料及び皮膚外用剤
CN102470124A (zh) * 2009-07-06 2012-05-23 国立大学法人东京农工大学 细胞保护剂
US20200140450A1 (en) * 2018-11-02 2020-05-07 Showa University Chemical method of producing smtp groups or smtp-7 and intermediates used in the method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HIRONOBU SAWADA; NAOKO NISHIMURA; ERIKO SUZUKI; JIE ZHUANG; KEIKO HASEGAWA; HIROYUKI TAKAMATSU; KAZUO HONDA; KEIJI HASUMI: "SMTP-7, a Novel Small-Molecule Thrombolytic for Ischemic Stroke: A Study in Rodents and Primates", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, vol. 34, no. 2, 15 February 2014 (2014-02-15), pages 235 - 241 *
MATSUMOTO NAOKI; SUZUKI ERIKO; ISHIKAWA MAKOTO; SHIRAFUJI TAKUMI; HASUMI KEIJI: "Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 52, 31 December 2014 (2014-12-31), pages 35826 - 38 *
SUZUKI ERIKO; NISHIMURA NAOKO; YOSHIKAWA TETSUYA; KUNIKIYO YUDAI; HASEGAWA KEIKO; HASUMI KEIJI: "Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys", PHARMACOLOGY RESEARCH & PERSPECTIVES, vol. 6, no. 6, 31 December 2018 (2018-12-31), pages 00448 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Also Published As

Publication number Publication date
KR20230173129A (ko) 2023-12-26
WO2022226013A1 (en) 2022-10-27
JP2024525239A (ja) 2024-07-11
CA3214630A1 (en) 2022-10-27
AU2022262593A1 (en) 2023-11-02
BR112023021803A2 (pt) 2024-01-23
US20240238252A1 (en) 2024-07-18
EP4326258A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
US6548079B1 (en) Moxifloxacin formulation containing common salt
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
KR101903351B1 (ko) 타펜타돌의 비경구 투여
KR20190017056A (ko) 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
JPWO1999059634A1 (ja) 抗炎症点眼剤
US7638556B2 (en) Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
US20220023302A1 (en) Pde9 inhibitors for treating sickle cell disease
EP4223313A1 (en) Pharmaceutical composition comprising acid-base neutralization combination and application thereof
EP1283043B1 (en) Ophthalmic solution
EP1543826B1 (en) Concentrated aqueous solution of ambroxol
EP2620153A1 (en) 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor
JP2020522572A (ja) レボドパ輸液
EP1941880B1 (en) Lotion preparation containing pyridonecarboxylic acid derivative
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
AU2005212355B2 (en) Controlled release formulations
WO2004098614A1 (ja) メチルコバラミン含有凍結乾燥製剤及びその製造方法
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
KR20170099911A (ko) 파라세타몰 주사 제제
WO2024224308A1 (en) Liquid parenteral formulations of bilastine free of cyclodextrins
WO2020188457A1 (en) Solutions for oral dosage
HK1179530B (en) Treatment of loss of sense of touch with saxitoxin derivatives
HK1179530A (en) Treatment of loss of sense of touch with saxitoxin derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240424

Address after: 22nd Floor, Jincang Wenhua Plaza, No. 1225 Nanjing West Road, Jing'an District, Shanghai

Applicant after: Jixing Pharmaceutical Hong Kong Ltd.

Country or region after: Hong-Kong

Address before: Massachusetts, USA

Applicant before: Bojian Massachusetts Co.,Ltd.

Country or region before: U.S.A.

TA01 Transfer of patent application right
CB02 Change of applicant information

Country or region after: Hong-Kong

Address after: Room 1902, 19th floor, Lee Garden Phase I, 33 Hysan Road, Causeway Bay, Hong Kong, China

Applicant after: Jixing Pharmaceutical Hong Kong Ltd.

Address before: 22nd Floor, Jincang Wenhua Plaza, No. 1225 Nanjing West Road, Jing'an District, Shanghai, 200040

Applicant before: Jixing Pharmaceutical Hong Kong Ltd.

Country or region before: Hong-Kong

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105250

Country of ref document: HK